Brazil’s Ministry of Health incorporated iptacopan into the Sistema Único de Saúde (SUS) for paroxysmal nocturnal hemoglobinuria (PNH) patients previously treated with a C5 inhibitor and with hemoglobin below 10 g/dL, while excluding ravulizumab and rejecting crovalimab and pegcetacoplan.

MARKET ACCESS · RARE DISEASE ACCESS · OCTOBER 30, 2026 · BRAZIL
Four decisions arrived in a single portaria — one incorporation, one exclusion, two rejections — all concerning how Brazil’s public health system treats paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Portaria SCTIE/MS nº 64, signed on 27 October 2026 and published in the Diário Oficial da União on 29 October, incorporates iptacopan into the Sistema Único de Saúde (SUS, Brazil’s universal public health system) while excluding ravulizumab.
The decision follows a recommendation issued by CONITEC (Comissão Nacional de Incorporação de Tecnologias no SUS), Brazil’s health-technology assessment body, at its 30th extraordinary meeting on 19 August 2026, per the CONITEC agenda document. That the Ministry of Health moved from recommendation to published portaria within roughly ten weeks suggests the administrative pipeline for this class of decisions operated without unusual delay.
180 days
Under Article 25 of Decree 7.646/2011, the Ministry of Health’s technical areas have a maximum of 180 days to make iptacopan available in the SUS following publication of Portaria SCTIE/MS nº 64.
What the portaria decides — and what it leaves open
Iptacopan is incorporated for a precisely defined population: adults with PNH who were previously treated with a C5 complement inhibitor and whose hemoglobin is below 10 g/dL, per the portaria as reported by Atlas Público. The population qualifier matters commercially and clinically — this is an option for patients with persistent anemia after C5 inhibitor treatment, not a first-line replacement. The technical areas of the Ministry of Health have up to 180 days to make the drug available, per Article 25 of Decree 7.646/2011, as cited in the portaria.
Ravulizumab, marketed by AstraZeneca, is excluded from the SUS for PNH. According to the patient association Crônicos do Dia a Dia (CDD), CONITEC had already recommended these decisions at its August meeting; the portaria formalises them and takes effect from its publication date, per Atlas Público.
Crovalimab and pegcetacoplan were both rejected. The portaria leaves a conditional path open: either product may be resubmitted to CONITEC if new facts emerge that could alter the assessment, per Atlas Público’s account of the regulatory text.
Two changes on two different clocks
The interval between the portaria’s publication and the moment iptacopan physically reaches SUS patients could extend to six months. The ravulizumab exclusion, by contrast, applies from the publication date, so the addition and the removal do not run on the same timetable.
For Novartis, the incorporation opens access to iptacopan through the SUS for the defined population. The population restriction means it is positioned after C5 inhibitors in the treatment sequence rather than displacing them at first line.
What to Watch
- How the Ministry of Health rolls out iptacopan supply within the 180-day window, and the clinical criteria it applies to dispensing
- AstraZeneca’s response to the ravulizumab exclusion, including any transition arrangements for patients currently treated with it through the SUS
- Any resubmission to CONITEC with new clinical or health-economic data for crovalimab or pegcetacoplan
The deeper signal is sequencing: the same portaria that admits a newer option removes an existing one, which suggests a SUS listing for a rare-disease drug can end in the very act that incorporates a successor.
SUS Market Access Timeline: Iptacopan Inclusion and Ravulizumab Exclusion
CONITEC Recommendation
19 August 2026
National Commission for Technology Incorporation (CONITEC) issued recommendation at its 30th extraordinary meeting.
Portaria Signed
27 October 2026
Ministry of Health signed Portaria SCTIE/MS nº 64 incorporating iptacopan for adults with paroxysmal nocturnal hemoglobinuria (PNH) previously treated with C5 inhibitor and hemoglobin below 10 g/dL.
Official Publication and Ravulizumab Exclusion
29 October 2026
Portaria published in Diário Oficial da União. Ravulizumab exclusion from SUS formulary became effective on the same date.
Implementation Deadline
180 days from 29 October 2026
Maximum implementation period under Decree 7.646/2011 Article 25 for SUS incorporation of iptacopan.
Sources: Portaria SCTIE/MS nº 64 (as_of: 2026-10-29); CONITEC agenda document (as_of: 2026-08-19); Decree 7.646/2011 Article 25
Why this is relevant
Patients
Adults with paroxysmal nocturnal hemoglobinuria (PNH) who have hemoglobin below 10 g/dL after treatment with a C5 inhibitor gain a new treatment option through the Sistema Único de Saúde (SUS); the Ministry of Health has up to 180 days to make iptacopan available, meaning access is approved but not yet operational.
Industry
Novartis gains SUS access for iptacopan through a CONITEC (Comissão Nacional de Incorporação de Tecnologias no SUS)-backed incorporation, while AstraZeneca’s ravulizumab is excluded from the SUS for PNH by the same portaria; crovalimab and pegcetacoplan may be resubmitted only if new facts emerge.
Payers
The SUS technical areas must activate iptacopan supply within the 180-day window set under Decree 7.646/2011, while the ravulizumab exclusion applies from the publication date of 29 October 2026.
Regulators
CONITEC’s 19 August 2026 recommendation has been converted into binding regulation via Portaria SCTIE/MS nº 64; the outstanding step is the operational rollout of iptacopan within the 180-day deadline.
Sources: CONITEC: Pauta 30ª Reunião Extraordinária — agenda document, 19 August 2026 · Atlas Público: Ministério da Saúde incorpora iptacopana ao SUS para hemoglobinúria paroxística noturna e exclui o ravulizumabe
Related coverage
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.







